Drug-related osteonecrosis of the jaw (MRONJ) is a rare but very serious side effect of certain medications. Although bisphosphonates are the most widely known of these drugs, biological antiresorptives, antiangiogenics and immunomodulators also have a place in the etiopathology of MRONJ. More recently, new drugs have also been associated with osteonecrosis of the jaw (ONJ). In the coming years, new drugs with mechanisms of action similar to those considered to have this negative effect will be marketed. Therefore, we can foresee the days when we will encounter drug-dependent jaw necrosis more frequently. In this case, it is very important that the dentists' knowledge about MRONJ is up-to-date.

It has been stated in many studies that osteonecrosis of the jaw is triggered by dental procedures and is very difficult to manage, especially in oncological patients. This pathology, which has various opinions for its treatment, is especially challenging for prosthesis and surgery specialists. Surgical reconstruction is not always possible for large jaw defects requiring prosthetic reconstruction, despite extensive surgical intervention and available evidence that laser surgery has the highest cure rates. In addition, surgical treatment may not be an option due to the patient's other systemic conditions.

Currently, there is no effective and accepted treatment for jaw necrosis. Therefore, it is essential to prevent new cases of MRONJ.